Iranian Red Crescent Medical Journal (IRCMJ)

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

Journal Metrics

News

Author Guidelines

Article Processing Charge

Side Effects of the Sinopharm/BBIBP COVID-19 Vaccine among Iranian Healthcare Workers: A Gender Assessment

Document Type : Research articles

Authors

1 Medical Student, Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

2 MD, PhD, Department of Infectious Diseases, Faculty of Medicine, West Fatemi St, Shahid Etemadzadeh St., AJA University of Medical Sciences, Tehran, Iran

3 PhD in Epidemiology, Department of Social Medicine, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran

4 PhD in Nursing, Department of Pediatric Nursing, Faculty of Nursing, AJA University of Medical Sciences, Tehran, Iran

5 Master of Sciences in Military Nursing, Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

6 Medical Student Mazandaran University of Medical Sciences, Sari, Iran

7 Assistant Professor of Pediatrics Department, Faculty of Medicine, Trauma Research Center, AJA University of Medical Sciences, Tehran, Iran

Abstract

Background: Since the outbreak of COVID-19, vaccination has been considered as an important measure against it. Side effects have always been an inseparable component of vaccination, which in this study, Sinopharm vaccine, its side effects and the differences of their manifestation amongst men and women have been investigated.
Objectives: This study aimed to compare the side effects of the Sinopharm vaccine among men and women working in some medical centers in Tehran, Iran.
Methods: This cross-sectional descriptive-analytical study on 890 healthcare workers of 7 medical centers in Tehran within 2 months, from late June to late August 2021. The samples were selected by the complete enumeration method, and the required data were collected using a questionnaire. Only those who received the Sinopharm vaccine at least 10 days before the study were included.
Results: Of 890 participants, 22.96% and 77.30% were women and men, respectively, and 65.8% of women and 78.1% of men were in the age range of 20-29 years. It was revealed that 74.75% of women and 26.16% of men had at least one side effect. The incidence of at least one side effect was significantly higher in women than in men (P<0.001). It was also found that 12 side effects were significantly higher in women than in men. Most men and women had side effects within the first 24 h after vaccination. There was no significant difference in taking therapeutic measures to reduce or minimize the post-vaccination complications between men and women; however, 9.4% of men and 27.2% of women reported a decline in their ability to perform daily activities as they were unable to do their everyday tasks the day after vaccination which was significantly different between the two groups (P<0.001).
Conclusion: The results showed that the occurrence rate of side effects after receiving the Sinopharm vaccine was significantly higher in women than in men. Moreover, women were significantly less able to perform daily routines than men.

Keywords

References
  1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. The lancet. 2020;395(10223):470-3. doi: 10.1016/S0140-6736(20)30185-9. [PubMed: 31986257]
  2. Organization WH. Naming the coronavirus disease (COVID-19) and the virus that causes it. https://www.who.int/ emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it. 2020.
  3. Dao TL, Hoang VT, Gautret P. Recurrence of SARS-CoV-2 viral RNA in recovered COVID-19 patients: a narrative review. Eur J Clin Microbiol Infect Dis. 2021;40(1):13-25. doi: 10.1007/s10096-020-04088-z. [PubMed: 33113040]
  4. Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and treatment of COVID‐19 patients in northeast Chongqing. J Med Virol. 2020;92(7):797-806. doi: 10.1002/jmv.25783. [PubMed: 32198776]
  5. WHO. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/. 2022.
  6. Chakraborty R, Parvez S. COVID-19: an overview of the current pharmacological interventions, vaccines, and clinical trials. Biochem Pharmacol. 2020;180:1-17. doi: 10.1016/j.bcp.2020.114184. [PubMed: 32739342]
  7. Saeed BQ, Al Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following sinopharm COVID-19 vaccination. Int J Infect Dis. 2021;111:219-26. doi: 10.1016/j.ijid.2021.08.013. [PubMed: 34384899]
  8. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis.2021;21(2):181-92. doi: 10.1016/S1473-3099(20)30843-4. [PubMed: 33217362]
  9. Reported Cases and Deaths by Country or Territory. worldometer. https://www.worldometers.info/coronavirus/. 2022.
  10. Baraniuk C. What do we know about China’s covid-19 vaccines? BMJ. 2021;373:912. doi: 10.1136/bmj.n912. [PubMed: 33836994]
  11. Organization WH. Evidence Assessment: Sinopharm/BBIBP COVID-19 vaccine. 2021.
  12. online: GTC-S-DDTA. Gender and sex-disaggregated data for COVID-19 e: https://globalhealth5050.org/the-sex-gender-and-covid-19-project/.
  13. Kovats S, Carreras E, Agrawal H. Sex steroid receptors in immune cells. Sex hormones and immunity to infection: Springer; 2010.
  14. Di Resta C, Ferrari D, Vigano M, Moro M, Sabetta E, Minerva M, et al. The gender impact assessment among healthcare workers in the SARS-CoV-2 vaccination-an analysis of serological response and side effects. Vaccines (Basel). 2021;9(5):1-13. doi: 10.3390/vaccines9050522. [PubMed: 34070196]
  15. Al Khames Aga QA, Alkhaffaf WH, Hatem TH, Nassir KF, Batineh Y, Dahham AT, et al. Safety of COVID‐19 vaccines. J Med Virol. 2021;93(12):6588-94. doi: 10.1002/jmv.27214. [PubMed: 34270094]
  16. Klugar M, Riad A, Mekhemar M, Conrad J, Buchbender M, Howaldt HP, et al. Side effects of mRNA-based and viral vector-based COVID-19 vaccines among German healthcare workers. Biology (Basel). 2021;10(8):1-21. doi: 10.3390/biology10080752. [PubMed: 34439984]
  17. Riad A, Pokorna A, Attia S, Klugarova J, Koscik M, Klugar M. Prevalence of COVID-19 Vaccine side effects among healthcare workers in the czech republic. J Clin Med. 2021;10(7):1-18. doi: 10.3390/jcm10071428. [PubMed: 33916020]
  18. Almufty HB, Mohammed SA, Abdullah AM, Merza MA. Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes Metab Syndr. 2021;15(5):102207. doi: 10.1016/j.dsx.2021.102207. [PubMed: 34280733]
  19. Jarynowski A, Semenov A, Kaminski M, Belik V. Mild adverse events of sputnik v vaccine extracted from russian language telegram posts via BERT deep learning model. J Med Internet Res. 2021;23(11):30529. doi: 10.2196/30529. [PubMed: 34662291]
  20. Abu Hammad O, Alduraidi H, Abu Hammad S, Alnazzawi A, Babkair H, Abu Hammad A, et al. Side effects reported
  21. by jordanian healthcare workers who received
  22. COVID-19 vaccines. Vaccines (Basel). 2021;9(6):1-10. doi: 10.3390/vaccines9060577. [PubMed: 34205917]
  23. Klein SL, Jedlicka A, Pekosz A. The Xs and Y of
  24. immune responses to viral vaccines. Lancet Infect Dis. 2010;10(5):338-49. doi: 10.1016/S1473-3099(10)70049-9. [PubMed: 20417416]
  25. Klein SL, Pekosz A. Sex-based biology and the rational
  26. design of influenza vaccination strategies. J Infect Dis. 2014;209(3):114-9. doi: 10.1093/infdis/jiu066. [PubMed: 24966191]
  27. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and
  28. the UK. Lancet. 2021;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. [PubMed: 33306989]
  29. Athavale AV. The Covid-19 Vaccine. J adv res med sci technol. 2021;8(1):29-35. doi: 0000-0002-8207-9589.
  30. Mathioudakis AG, Ghrew M, Ustianowski A, Ahmad S, Borrow R, Papavasileiou LP, et al. Self-reported real-world safety and reactogenicity of covid-19 vaccines: A vaccine recipient survey. Life (Basel). 2021;11(3):249. doi: 10.3390/life11030249. [PubMed: 33803014]
  31. Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;
  32. (10240):1845-54. doi: 10.1016/S0140-6736(20)31208-3. [PubMed: 32450106]
  33. Kadali RAK, Janagama R, Peruru S, Malayala SV. Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. Int J Infect Dis. 2021;106:376-81. doi: 10.1016/j.ijid.2021.04.047. [PubMed: 33866000]
Iranian Red Crescent Medical Journal (IRCMJ)
Volume 24, Issue 8 - Serial Number 8
2022
Files
History
  • Receive Date: 21 February 2022
  • Revise Date: 26 May 2024
  • Accept Date: 27 January 2024
  • First Publish Date: 27 January 2024
  • Publish Date: 01 August 2022
Share
How to cite
Statistics